---
title: "Artelo Biosciences reports positive preclinical data for ART26.12 in spinal cord injury neuropathic pain model"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291417516.md"
description: "Artelo Biosciences reported positive preclinical data for ART26.12, a selective FABP5 inhibitor, in a mouse model of spinal cord injury-related neuropathic pain. The study demonstrated reduced mechanical hypersensitivity, lower spontaneous pain behaviors, and suppressed nociceptor hyperexcitability with oral dosing. Positioned as a potential first-in-class non-opioid chronic pain therapy, the program remains in Phase 1 clinical development."
datetime: "2026-07-01T12:42:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291417516.md)
  - [en](https://longbridge.com/en/news/291417516.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291417516.md)
---

# Artelo Biosciences reports positive preclinical data for ART26.12 in spinal cord injury neuropathic pain model

-   Artelo reported positive preclinical data for ART26.12 in a mouse model of spinal cord injury-related neuropathic pain. \* Study showed reduced mechanical hypersensitivity, lower spontaneous pain behaviors, suppressed nociceptor hyperexcitability, improved outcomes with oral dosing. \* Company positioned ART26.12, a selective FABP5 inhibitor, as a potential first-in-class non-opioid chronic pain therapy; program remains in Phase 1. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010842PRIMZONEFULLFEED9755539) on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)

## Related News & Research

- [Artelo Biosciences reports positive preclinical data for ART27.13 in paclitaxel-induced peripheral neuropathy model](https://longbridge.com/en/news/292495956.md)
- [Artelo Biosciences says Phase 1 study shows FABP5 inhibitor ART26.12 is well tolerated, with linear pharmacokinetics](https://longbridge.com/en/news/291147934.md)
- [Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall?](https://longbridge.com/en/news/294229928.md)
- [Zoetis says UK regulator approves Portela for cat osteoarthritis pain](https://longbridge.com/en/news/294387450.md)
- [OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial](https://longbridge.com/en/news/293646761.md)